Jacobs Levy Equity Management
TVTX icon

Jacobs Levy Equity Management’s Travere Therapeutics TVTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
369,193
+100,267
+37% +$3M 0.05% 293
2025
Q4 		$10.3M Sell
268,926
-49,220
-15% -$1.6M 0.04% 301
2025
Q3 		$7.6M Sell
318,146
-417,105
-57% -$7.84M 0.03% 344
2025
Q2 		$10.9M Sell
735,251
-127,837
-15% -$2.12M 0.04% 289
2025
Q1 		$15.5M Sell
863,088
-1,311,125
-60% -$26.6M 0.06% 267
2024
Q4 		$37.9M Buy
2,174,213
+583,836
+37% +$10.3M 0.13% 155
2024
Q3 		$22.2M Sell
1,590,377
-299,467
-16% -$3.12M 0.09% 218
2024
Q2 		$15.5M Buy
1,889,844
+765,159
+68% +$5.15M 0.06% 269
2024
Q1 		$8.67M Sell
1,124,685
-593,513
-35% -$5.01M 0.04% 322
2023
Q4 		$15.4M Buy
1,718,198
+46,428
+3% +$338K 0.08% 248
2023
Q3 		$14.9M Buy
1,671,770
+146,970
+10% +$2.07M 0.09% 211
2023
Q2 		$23.4M Buy
1,524,800
+59,048
+4% +$1.07M 0.14% 176
2023
Q1 		$33M Buy
1,465,752
+581,490
+66% +$12.4M 0.2% 128
2022
Q4 		$18.6M Buy
884,262
+156,148
+21% +$3.31M 0.13% 201
2022
Q3 		$17.9M Buy
728,114
+170,211
+31% +$4.4M 0.14% 184
2022
Q2 		$13.5M Sell
557,903
-367,541
-40% -$9.24M 0.1% 228
2022
Q1 		$23.8M Sell
925,444
-13,648
-1% -$362K 0.16% 158
2021
Q4 		$29.1M Sell
939,092
-93,306
-9% -$2.63M 0.2% 128
2021
Q3 		$25M Buy
1,032,398
+241,467
+31% +$4.44M 0.17% 155
2021
Q2 		$11.5M Buy
790,931
+149,759
+23% +$2.95M 0.08% 265
2021
Q1 		$16M Sell
641,172
-4,878
-0.8% -$135K 0.12% 208
2020
Q4 		$17.6M Sell
646,050
-23,325
-3% -$545K 0.15% 162
2020
Q3 		$12.4M Sell
669,375
-14,871
-2% -$289K 0.13% 177
2020
Q2 		$14M Buy
684,246
+84,355
+14% +$1.34M 0.15% 162
2020
Q1 		$8.75M Sell
599,891
-24,676
-4% -$371K 0.11% 200
2019
Q4 		$8.87M Buy
624,567
+215,474
+53% +$2.75M 0.09% 267
2019
Q3 		$4.74M Buy
409,093
+211,058
+107% +$3.49M 0.06% 346
2019
Q2 		$3.98M Buy
198,035
+45,100
+29% +$890K 0.06% 389
2019
Q1 		$3.46M Buy
152,935
+124,319
+434% +$2.75M 0.05% 398
2018
Q4 		$648K Sell
28,616
-490
-2% -$12.2K 0.01% 692
2018
Q3 		$836K Buy
29,106
+1,376
+5% +$39.3K 0.01% 679
2018
Q2 		$756K Sell
27,730
-1,470
-5% -$39.1K 0.01% 722
2018
Q1 		$653K Buy
29,200
+6,800
+30% +$162K 0.01% 728
2017
Q4 		$472K Buy
+22,400
New +$512K 0.01% 766

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's TVTX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Travere Therapeutics (TVTX) stake by 37% in Q1 2026, buying an estimated $3M and bringing the position to 369,193 shares worth $11M. The position accounts for 0.05% of the portfolio, ranked #293.

Jacobs Levy Equity Management first reported a position in TVTX in Q4 2017 and has held it in 34 quarters since. The position peaked at $37.9M in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Jacobs Levy Equity Management held 369,193 shares of Travere Therapeutics worth $11M as of Q1 2026.
  • Jacobs Levy Equity Management bought 100,267 Travere Therapeutics shares in Q1 2026, an estimated $3M.
  • Travere Therapeutics made up 0.05% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #293 holding.
  • Jacobs Levy Equity Management first reported a position in Travere Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Jacobs Levy Equity Management's Travere Therapeutics position peaked at $37.9M in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.